SCHEDULE: Deep Track Capital Reports 7.45% Stake in Nurix Therapeutics

Deep Track Capital, LP, along with affiliated entities, has disclosed a beneficial ownership of 7.45% of Nurix Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G.
• As of June 30, 2026, these entities collectively beneficially own 7,736,455 shares of Nurix Therapeutics, Inc. common stock.
• This represents 7.45% of the class of securities outstanding.
• The filing indicates shared voting and dispositive power for these shares.
• David Kroin is identified as a control person for Deep Track Capital, LP.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a passive ownership stake without new strategic information or significant changes in holdings.

Positives

• Disclosure of a significant passive ownership stake (7.45%) in Nurix Therapeutics, Inc. by Deep Track Capital and its affiliates.
• The filing confirms the outstanding shares of Nurix Therapeutics, Inc. as 103,781,683 as of June 30, 2026.

Negatives

• The filing does not provide any new strategic insights or indicate any active involvement in the company's management or operations.
• The ownership stake, while significant, is reported as a passive holding, suggesting no immediate intent to influence control.

Risks

• Potential for future changes in ownership by Deep Track Capital, which could impact market sentiment.
• The passive nature of the holding means the reporting persons are not actively driving strategy, which could be a risk if the company requires active investor engagement.

Future Outlook

This filing is primarily a reporting of existing ownership and does not contain forward-looking statements or specific guidance from the reporting persons regarding future actions or outlook for Nurix Therapeutics, Inc.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant institutional ownership, even if passive, can influence market perception and potential future strategic shifts within the biotechnology sector. Nurix Therapeutics operates in the targeted protein degradation space, a competitive and rapidly evolving field.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's passive stake, which may be viewed positively for stability but lacks active strategic engagement.
• Management: The filing does not indicate any intent to influence management decisions, suggesting a continuation of the current governance structure.
• Creditors: No direct impact on creditors is indicated by this passive ownership filing.

Next Steps

• The reporting persons will continue to monitor their investment in Nurix Therapeutics, Inc.
• Future amendments to this filing will be made if ownership levels change significantly or if the nature of the holding changes.

Key Dates

Recommendation

The filing reports a passive increase in ownership to 7.45% by Deep Track Capital and its affiliates. As this is a Schedule 13G filing, it indicates a passive investment without intent to influence control. While a significant stake, it does not provide new strategic information or operational performance data that would warrant a buy or sell recommendation. Therefore, a 'hold' is appropriate pending further developments or more substantive company announcements.

Keywords

Nurix Therapeutics, Deep Track Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology